Why is Pfizer Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 0.77% and Operating profit at 4.71% over the last 5 years
2
With ROE of 18.4, it has a Very Expensive valuation with a 5.3 Price to Book Value
- The stock is trading at a fair value compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -7.76%, its profits have risen by 14.4% ; the PEG ratio of the company is 2
3
Below par performance in long term as well as near term
- Along with generating -7.76% returns in the last 1 year, the stock has also underperformed BSE500 in the last 3 years, 1 year and 3 months
How much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Pfizer for you?
Medium Risk, Medium Return
Absolute
Risk Adjusted
Volatility
Pfizer
-7.76%
-0.31
24.67%
Sensex
-3.81%
-0.28
13.58%
Quality key factors
Factor
Value
Sales Growth (5y)
0.77%
EBIT Growth (5y)
4.71%
EBIT to Interest (avg)
67.25
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.72
Sales to Capital Employed (avg)
0.70
Tax Ratio
25.95%
Dividend Payout Ratio
98.34%
Pledged Shares
0
Institutional Holding
19.45%
ROCE (avg)
51.90%
ROE (avg)
17.67%
Valuation Key Factors 
Factor
Value
P/E Ratio
29
Industry P/E
37
Price to Book Value
5.25
EV to EBIT
21.53
EV to EBITDA
20.21
EV to Capital Employed
16.37
EV to Sales
7.41
PEG Ratio
1.99
Dividend Yield
1.55%
ROCE (Latest)
72.81%
ROE (Latest)
18.35%
Loading Valuation Snapshot...
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
Technical Movement
9What is working for the Company
CASH AND CASH EQUIVALENTS(HY)
Highest at Rs 3,110.76 cr
DEBTORS TURNOVER RATIO(HY)
Highest at 13.86 times
NET SALES(Q)
Highest at Rs 653.17 cr
PBDIT(Q)
Highest at Rs 247.56 cr.
OPERATING PROFIT TO NET SALES(Q)
Highest at 37.90%
PBT LESS OI(Q)
Highest at Rs 231.84 cr.
PAT(Q)
Highest at Rs 204.47 cr.
EPS(Q)
Highest at Rs 44.69
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Pfizer
Net Sales - Quarterly
Highest at Rs 653.17 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 247.56 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Highest at 37.90%
in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 231.84 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 204.47 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 44.69
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Cash and Cash Equivalents - Half Yearly
Highest at Rs 3,110.76 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debtors Turnover Ratio- Half Yearly
Highest at 13.86 times
in the last five half yearly periodsMOJO Watch
Company has been able to settle its Debtors faster
Debtors Turnover Ratio






